Clinical Research Trials on Liver Cancer

The physicians and health care team at the UPMC Liver Cancer Center are engaged in clinical research trials to determine the latest state-of-the-art treatment for liver tumors.

For more information about clinical research at the UPMC Liver Cancer Center, please contact us.

Active Clinical Research Protocols

Study Title

NSABP PROTOCOL FC-6: A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 Plus Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer with Metastases Confined to the Liver

Purpose

To evaluate the surgical conversion rate using cytotoxic combination chemotherapy, FOLFOX7, the biologic therapy with cetuximab.

Goal

To downstage (up to three, two-month cycles) followed by liver resection +/- RFA.

Principal Investigator

David A. Geller, MD, FACS

Study Title

Phase I/II Trial Testing Immunization with AFP Plus GM-CSF Plasmid and AFP Adenoviral Vector Boost in Patients with Hepatocellular Carcinoma (HCC)

Purpose

To investigate immune response after injection of AFP virus in patients with stable disease following prior therapy.

Co-Principal Investigator

David A. Geller, MD, FACS

Study Title

LC Drug Eluting Bead for Regional Chemoembolization to Downstage or Bridge Unresectable Hepatocellular Carcinoma (HCC) to Liver Transplantation

Purpose

To test the LC Drug Eluting Bead in combination with Doxorubicin for regional chemoembolization as a method for downstaging or bridging patients to liver transplantation.

Principal Investigator

David A. Geller, MD, FACS

Study Title

Computer-Mediated Strategies for Symptom Management

Purpose

To improve quality of life for individuals diagnosed with hepatobiliary carcinoma and their family caregivers.

Principal Investigator

Jennifer Steel, PhD

Study Title

Analysis of the Cytokine-Immunological Model of Cancer

Purpose

To understand the relationship between cancer-related symptoms (e.g., fatigue, pain), associated biomarkers (e.g., cytokines, Natural Killer cells), and the individual's response to treatment.

Principal Investigator

Jennifer Steel, PhD

Upcoming Clinical Research Protocols

  • NSABP C-11 study — A Phase III, multicenter, randomized trial that will evaluate the difference in recurrence-free survival between patients with resectable hepatic colorectal metastases receiving perioperative (preoperative plus postoperative) chemotherapy and those receiving only postoperative chemotherapy following hepatic surgery to resect colorectal metastases.
  • Therasphere (STO) trial — To evaluate Therasphere in the treatment of patients with unresectable hepatocellular carcinoma in whom treatment with standard-of-care sorofenib therapy is planned.

Clinical Research Interests

Recent Clinical Research Protocols

  • A randomized controlled trial of TheraSphere® vs. Cisplatin-based transarterial chemoembolization (TACE) in the treatment of unresectable hepatocellular carcinoma (HCC).
  • A phase II study of Trisenox in the treatment of unresectable HCC.
  • A phase III placebo-controlled trial of Sorafenib in patients with advanced unresectable HCC.
  • Hepatic arterial cisplatin + Adriamycin with or without Lipiodol for HCC, a prospective randomized trial.
  • Thymitaq, a multicenter study for the treatment of advanced-stage HCC.
  • Novel molecular markers for the diagnosis of HCC circulating micro-metastases.
  • Irissa (EGF receptor antibody) for HCC — a multicenter trial.
  • Radiofrequency-induced necrosis within hepatic tissue by a bipolar electrode.

For more information about active clinical research, interests, or protocols at the UPMC Liver Cancer Center, please contact us.

©  UPMC | Affiliated with the University of Pittsburgh Schools of the Health Sciences
Supplemental content provided by A.D.A.M. Health Solutions. All rights reserved.

For help in finding a doctor or health service that suits your needs, call the UPMC Referral Service at 412-647-UPMC (8762) or 1-800-533-UPMC (8762). Select option 1.

UPMC is an equal opportunity employer. UPMC policy prohibits discrimination or harassment on the basis of race, color, religion, ancestry, national origin, age, sex, genetics, sexual orientation, marital status, familial status, disability, veteran status, or any other legally protected group status. Further, UPMC will continue to support and promote equal employment opportunity, human dignity, and racial, ethnic, and cultural diversity. This policy applies to admissions, employment, and access to and treatment in UPMC programs and activities. This commitment is made by UPMC in accordance with federal, state, and/or local laws and regulations.

Medical information made available on UPMC.com is not intended to be used as a substitute for professional medical advice, diagnosis, or treatment. You should not rely entirely on this information for your health care needs. Ask your own doctor or health care provider any specific medical questions that you have. Further, UPMC.com is not a tool to be used in the case of an emergency. If an emergency arises, you should seek appropriate emergency medical services.

For UPMC Mercy Patients: As a Catholic hospital, UPMC Mercy abides by the Ethical and Religious Directives for Catholic Health Care Services, as determined by the United States Conference of Catholic Bishops. As such, UPMC Mercy neither endorses nor provides medical practices and/or procedures that contradict the moral teachings of the Roman Catholic Church.

© UPMC
Pittsburgh, PA, USA UPMC.com